NCT00239109已完成4 期
Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia: A Six Months, Double Blind Randomized, Parallel Group Study.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.7 个研究点 分布在 1 个国家目标入组 112 人开始时间: 2003年4月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 112
- 试验地点
- 7
- 主要终点
- To estimate and compare the effects of ziprasidone vs olanzapine on body weight in the treatment of patients with schizophrenia.
研究概览
简要总结
- Various studies suggest that patients treated with Olanzapine can experience a substantial weight gain, while no changes have been observed in patients treated with Ziprasidone. Negative consequences on lipid and glucose profiles have also been observed in patients treated with Olanzapine. Most of the available data belong to short-term studies. However, for most clinical trials the primary variable was an efficacy variable, and included the weight assessment as a secondary variable; they also lack a systematic monitoring of some variables that can play a role in weight gain, as the level of exercise, appetite increase, etc. and we have considered of importance their inclusion in this protocol. Previous studies did not assess visceral fat using widely standardized parameters as the waist index, which at certain levels is considered an indicator of the cardiovascular risk, or leptine, highly correlated to the body fat storage. We would like to fit the recently published American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists and North American Association for the Study of Obesity Antipsychotic, obesity and diabetes mellitus consensus.22
- Schizophrenic patients show a 4-fold probability to die as a consequence of cardiovascular problems compared to the normal population. The antipsychotic treatment can contribute to increase this risk favoring weight gain and the appearance of cardiovascular risk factors associated to obesity (blood hypertension, hyperlipidemia, type II Diabetes Mellitus). We intend to obtain a complete cardiovascular risk profile of patients, as well as its change during antipsychotic treatment, including primary cardiovascular risk factors in addition to the analysis of markers that have recently been linked to cardiovascular risk (as reactive protein C).
- The study will evaluate the risk of hyperglycemia, insulin resistance and Diabetes Mellitus, and will investigate the association between glucose homeostasis abnormalities and weight gain in the treated patients. Likewise, adiponectine, secreted from adipocytes and a possible link between obesity and insulin resistance will be determined; recent studies show an adiponectine decrease in humans with insulin resistance and obesity; furthermore, prospective studies have shown these changes could predict a higher risk of DM development.
- Changes have been introduced in the complete evaluation of the patient's metabolic and cardiovascular profiles with the advice, and under the coordination of endocrinologists after a complete review of the subject
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with a primary diagnosis of schizophrenia using the DSM-IV-TR criteria
- •Patient's clinical condition should justify treatment initiation with a new antipsychotic drug.
排除标准
- •Patients at immediate risk of committing harm to self or others
- •Concurrent treatment with antipsychotic agents after randomization.
结局指标
主要结局
To estimate and compare the effects of ziprasidone vs olanzapine on body weight in the treatment of patients with schizophrenia.
次要结局
- PANSS total score; change from baseline CGI severity; change from baseline CGI - Improvement PANSS negative subscale score; change from baseline DSM IV axis V Patient preference scale (PPS) Heath Utility Index Mark III BMI , Qaist Index
研究者
研究点 (7)
Loading locations...
相似试验
进行中（未招募）
不适用
Influence of treatment of olanzapine and ziprasidone on transcapillary glucose transport in human skeletal muscle - Olanzapine or ziprasidone on transcapillary glucose transportHealthy volunteersEUCTR2004-002147-27-ATDepartment of General Psychiatry30
终止
4 期
Ziprasidone And Olanzapine's Outcomes In ManiaAcute ManiaBipolar Disorder, ManicNCT00329108Pfizer's Upjohn has merged with Mylan to form Viatris Inc.29
已完成
不适用
Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar DisorderDepressive Disorder, MajorSchizophreniaSchizoaffective DisorderBipolar DisorderNCT00179062Vanderbilt University300
进行中（未招募）
不适用
ZOOM STUDY ZIPRASIDONE AND OLANZAPINE S OUTCOMES IN MANIA A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY, COMPARING THE EFFICACY AND TOLERABILITY OF ZIPRASIDONE ZELDOX 63194;, GEODON 63194; VS OLANZAPINE ZYPREXA 63194; IN THE TREATMENT AND MAINTENANCE OF RESPONSE IN PATIENTS WITH ACUTE MANIA - ZOOM STUDY ZIPRASIDONE AND OLANZAPINE S OUTCOMES IN MANIAAcute maniaMedDRA version: 6.1Level: PTClassification code 10004939EUCTR2005-004391-21-ITPFIZER352
已完成
4 期
Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective TrialSchizophrenia, Schizoaffective DisorderNCT00224315Central Institute of Mental Health, Mannheim24